确定米兰标准以预测局部区域治疗后肝移植后HCC复发的最佳影像学标准和检查方式
该回顾性研究纳入121例接受局部区域治疗且同时有肝脏动态CT和MRI的HCC患者,用CT/MRI与mRECIST/LI-RADS TRA交叉组合四种方法判定米兰标准。竞争风险回归显示,以MRI联合mRECIST判定超出米兰标准与复发独立相关(HR 6.926,P=0.001)。MRI联合mRECIST是预测移植后复发的最佳影像学方法。
要点
- MRI联合mRECIST判定米兰标准是预测移植后HCC复发的最佳术前影像方法。
- 采用mRECIST时,MRI在移植后3年和5年的预测AUC均显著高于CT。
- 以病理为参考标准,MRI联合LI-RADS TRA的敏感度高于CT联合LI-RADS TRA或MRI联合mRECIST。
核心结论
- MRI联合mRECIST是判定米兰标准、预测既往接受局部区域治疗的HCC患者移植后复发的最佳影像学方法。
研究设计与样本
- 回顾性研究,纳入121例接受局部区域治疗且同时有肝脏动态CT和MRI的HCC患者,以病理为参考标准。
诊断标准与关键数值
- 以MRI联合mRECIST判定超出米兰标准与复发独立相关(HR 6.926,P=0.001)。
- 采用mRECIST时,MRI在移植后3年的AUC为0.756,CT为0.597(P=0.012)。
- 采用mRECIST时,MRI在移植后5年的AUC为0.733,CT为0.588(P=0.024)。
- 以病理为参考标准,MRI联合LI-RADS TRA的敏感度为61.5%,高于CT联合LI-RADS TRA的30.8%(P<0.001)和MRI联合mRECIST的38.5%(P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: We aimed to investigate the optimal radiologic method to determine Milan criteria (MC) for the prediction of recurrence in patients who underwent locoregional treatment (LRT) for hepatocellular carcinoma (HCC) and subsequent liver transplantation (LT).
METHODS: This retrospective study included 121 HCC patients who underwent LRT and had both liver dynamic CT and MRI. They were classified with MC using four cross combinations of two imaging modalities (CT and MRI) and two diagnostic criteria (modified Response Evaluation Criteria in Solid Tumors [mRECIST] and Liver Imaging Reporting and Data System treatment response algorithm [LI-RADS TRA]). Competing risk regression was performed to analyze the time to recurrence after LT. The predictive abilities of the four methods for recurrence were evaluated using the time-dependent area under the curve (AUC).
RESULTS: Competing risk regression analyses found that beyond MC determined by MRI with mRECIST was independently associated with recurrence (hazard ratio, 6.926; p = 0.001). With mRECIST, MRI showed significantly higher AUCs than CT at 3 years and 5 years after LT (0.597 vs. 0.756, p = 0.012 at 3 years; and 0.588 vs. 0.733, p = 0.024 at 5 years). Using the pathologic reference standard, MRI with LI-RADS TRA showed higher sensitivity (61.5%) than CT with LI-RADS TRA (30.8%, p < 0.001) or MRI with mRECIST (38.5%, p < 0.001).
CONCLUSIONS: MRI with mRECIST was the optimal radiologic method to determine MC for the prediction of post-LT recurrence in HCC patients with prior LRT.
KEY POINTS: • MRI with modified RECIST (mRECIST) is the optimal preoperative method to determine Milan criteria for the prediction of post-transplant HCC recurrence in patients with prior locoregional treatment. • With mRECIST, MRI was better than CT for the prediction of post-transplant recurrence.
引用
- Seo, Joo, Park, et al. Optimal imaging criteria and modality to determine Milan criteria for the prediction of post-transplant HCC recurrence after locoregional treatment. Eur Radiol. 2022. PMID: 35821427. doi:10.1007/s00330-022-08977-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。